Relative risk of CML, AML, and MDS among first-degree relatives of MPN patients
| Proband . | CML . | AML . | MDS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients . | Controls . | RR (95% CI) . | Patients . | Controls . | RR (95% CI) . | Patients . | Controls . | RR (95% CI) . | |
| Any MPN | 11 | 24 | 1.9 (0.9-3.8) | 34 | 108 | 1.3 (0.9-1.9) | 5 | 13 | 1.6 (0.6-4.4) |
| PV | 7 | 13 | 2.2 (0.9-5.5) | 16 | 62 | 1.0 (0.6-1.8) | 3 | 5 | 2.4 (0.6-10.2) |
| ET | 1 | 4 | 1.0 (0.1-8.8) | 11 | 25 | 1.8 (0.9-3.8) | 0 | 7 | NA |
| MF | 2 | 3 | 2.7 (0.5-15.8) | 3 | 9 | 1.4 (0.3-5.3) | 1 | 0 | ND |
| MPN NOS | 1 | 4 | 1.0 (0.2-9.7) | 4 | 12 | 1.4 (0.5-4.3) | 1 | 1 | 4.6 (0.3-75.9) |
| Proband . | CML . | AML . | MDS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients . | Controls . | RR (95% CI) . | Patients . | Controls . | RR (95% CI) . | Patients . | Controls . | RR (95% CI) . | |
| Any MPN | 11 | 24 | 1.9 (0.9-3.8) | 34 | 108 | 1.3 (0.9-1.9) | 5 | 13 | 1.6 (0.6-4.4) |
| PV | 7 | 13 | 2.2 (0.9-5.5) | 16 | 62 | 1.0 (0.6-1.8) | 3 | 5 | 2.4 (0.6-10.2) |
| ET | 1 | 4 | 1.0 (0.1-8.8) | 11 | 25 | 1.8 (0.9-3.8) | 0 | 7 | NA |
| MF | 2 | 3 | 2.7 (0.5-15.8) | 3 | 9 | 1.4 (0.3-5.3) | 1 | 0 | ND |
| MPN NOS | 1 | 4 | 1.0 (0.2-9.7) | 4 | 12 | 1.4 (0.5-4.3) | 1 | 1 | 4.6 (0.3-75.9) |
All estimates were adjusted for sex of first-degree relative.
CML indicates chronic myeloid leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; RR, relative risk; CI, confidence interval; MPN, myeloproliferative neoplasm; PV, polycythemia vera; ET, essential thrombocythemia; MF, myelofibrosis; NOS, unclassifiable; NA, not applicable; and ND, not done.